Chronic heart failure (CHF) is a common complication and cause of death in
dialysis patients. Although several clinical guidelines and expert consensus on
heart failure (HF) in the general population have been issued in China and
abroad, due to abnormal renal function or even no residual renal function (RRF)
in dialysis patients, the high number of chronic complications, as well as the
specificity, variability, and limitations of hemodialysis (HD) and peritoneal
dialysis (PD) treatments, there are significant differences between dialysis
patients and the general population in terms of the treatment and management of
HF. The current studies are not relevant to all dialysis-combined HF populations,
and there is an urgent need for high-quality studies on managing HF in dialysis
patients to guide and standardize treatment. After reviewing the existing
guidelines and literature, we focused on the staging and diagnosis of HF,
management of risk factors, pharmacotherapy, and dialysis treatment in patients
on dialysis. Based on evidence-based medicine and clinical trial data, this
report reflects new perspectives and future trends in the diagnosis and treatment
of HF in dialysis patients, which will further enhance the clinicians’
understanding of HF in dialysis patients.